CLGN Stock Analysis: Buy, Sell, or Hold?
CLGN - CollPlant Biotechnologies Ltd Ordinary Shares
$0.34
-0.02 (-4.43%)
▼
5d:
+0.42%
30d:
-21.11%
90d:
-52.69%
BUY
HIGH Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: May 27, 2026
0d
Get Alerted When CLGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CLGN shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: CLGN shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: CLGN is currently trading at $0.34, which is considered oversold relative to its 30-day fair value range of $0.34 to $0.42. From a valuation perspective, the stock is trading at a discount (Forward PE: -1.9) compared to its historical average (3.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CLGN is in a downtrend. Immediate support is located at $0.30, while resistance sits at $0.42. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.12 (+3205.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CLGN is in a downtrend. Immediate support is located at $0.30, while resistance sits at $0.42. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.12 (+3205.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.34 -
$0.42
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.4%)
- BULLISH: Trading 3205.6% below Wall St target ($11.12)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$0.34 -
$0.42
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.31
Resistance Level
$0.42
Current Trend
Downtrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.87
Wall Street Target
$11.12
(+3205.6%)
Revenue Growth (YoY)
-96.4%
PE vs Historical
-1.9 vs 3.5
CHEAP
Share & Embed Analysis
Last updated: June 24, 2026 11:12 PM ET
Data refreshes hourly during market hours. Next update: 12:12 AM
Data refreshes hourly during market hours. Next update: 12:12 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 57 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 58 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 56 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
